I'm about to go to bed now, but there's something that's been gnoring in my mind...
if during a combination therapy trial, adverse reactions are observed in a participant, how do they work out which drug caused the reaction? I'll probably answer my own question here by saying that we're (IMU) providing a platform to carry the other company's drug and trials to date don't show any adverse effects from our drug as yet, but what if???
Just curious, not overly concerned as I'm not a scientist.
Any thought's anyone?
Why IMU is a multi multi bagger, page-5636
-
- There are more pages in this discussion • 19,424 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.7¢ |
Change
0.003(5.56%) |
Mkt cap ! $417.2M | |||
| Open | High | Low | Value | Volume |
| 5.5¢ | 5.8¢ | 5.2¢ | $2.499M | 45.00M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1921794 | 5.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.7¢ | 1368288 | 7 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| IMU (ASX) Chart |